Overview

• The plan replaces AstraZeneca’s Nasdaq ADRs with a direct listing of ordinary shares on the NYSE, creating a single share that trades in London, Stockholm and New York.
• The company says it will remain headquartered, listed and tax resident in the UK, with continued inclusion in the FTSE 100 and OMX Stockholm 30.
• A Circular and related documents have been published and filed to the FCA’s National Storage Mechanism ahead of the General Meeting on 3 November 2025.
• News reports cite an expected NYSE start date of 2 February 2026, subject to shareholder approval and any required regulatory steps.
• Shares rose about 0.7% to 1.2% on the news as analysts called the move a knock back for London and noted AstraZeneca’s growing US focus, including a reported $50bn investment plan.